Scientists said they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.
Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world’s biggest annual oncology meeting.
U.S. health regulators approved Merck & Co.’s Keytruda in combination with chemotherapy for previously untreated advanced lung cancer.
The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, announced the initial enrollment of its first clinical trial in a new program aimed at dramatically increasing knowledge of how the immune system works.
The Human Vaccines Project and Vanderbilt University Medical Center announced that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system.
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists told Reuters.
Lexington, Mass.-based Agenus quietly filed with the U.S. Securities and Exchange Commission (SEC) that it was halting the company’s clinical trial of its cancer vaccine Prophage.
The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co.’s Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.
Merck & Co. Inc. reported better-than-expected U.S. quarterly sales for its key cancer drug Keytruda and forecast largely in-line 2017 results.
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb, but is making up lost ground.